Author: Vigor Forty Editorial Team
Medically Reviewed By: Editorial Review Board
Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice. Consult your physician before beginning a new exercise program, especially if you have an underlying health condition or are immunocompromised. Read our full Medical Disclaimer.
📌 Key Takeaways
- Testosterone decline after 40 is gradual and variable; not all men experience symptomatic hypogonadism, but those who do may face impacts on bone density, muscle mass, mood, and cardiovascular health.
- “Low T” is a clinical diagnosis requiring both consistent symptoms and two low morning testosterone levels, yet direct-to-consumer marketing in the U.S. often bypasses this rigor, while European systems remain more conservative.
- Screening protocols, lab reference ranges, and treatment philosophies diverge sharply: the U.S. trend leans toward liberal testing and prescribing, France and Poland are highly conservative, and Germany sits in the middle with a regulated but accessible pathway.
- Testosterone therapy can improve bone density, body composition, and libido in truly hypogonadal men, but it is not a longevity elixir; inappropriate use carries risks including polycythemia, sleep apnea exacerbation, and potential cardiovascular concerns.
- Lifestyle—resistance training, adequate sleep, weight management, and stress reduction—remains the most powerful, safest way to support endogenous testosterone production in the 40+ man.
Introduction
Testosterone has been marketed as the hormone of vitality, virility, and vigor. Men in their 40s, noticing slower recovery from workouts, a softer midsection, or a dip in libido, are increasingly asking: “Is my testosterone low?” The answer, however, is rarely straightforward. Testosterone levels naturally decline by about 1–2% per year after age 40, but the clinical syndrome of hypogonadism—defined by both persistently low testosterone and specific symptoms—affects only a fraction of aging men.
What complicates the picture is geography. A 45-year-old man in Dallas may be offered testosterone therapy based on a single borderline blood test and a telehealth questionnaire, while his counterpart in Lyon, Warsaw, or Berlin will encounter a far more stringent diagnostic process. These differences reflect not just medical evidence, but cultural attitudes, regulatory frameworks, and the influence of the pharmaceutical industry. This article deciphers the science of testosterone after 40, unpacks the country-by-country approach to screening and treatment, and provides a roadmap for making informed, personalized decisions—whether you’re in the U.S., Poland, Germany, or France.
Understanding Testosterone Physiology in Midlife
Testosterone is produced primarily in the testes, regulated by the hypothalamic-pituitary-gonadal axis. In men, it supports spermatogenesis, libido, muscle protein synthesis, bone mineralization, erythropoiesis, and mood regulation. After 40, total testosterone levels decline, but a larger fraction becomes bound to sex hormone-binding globulin (SHBG), reducing free and bioavailable testosterone—the forms that can enter cells and exert effects.
Symptoms of clinically low testosterone (hypogonadism) may include:
- Reduced libido and erectile dysfunction
- Loss of morning erections
- Fatigue, low mood, irritability
- Decreased muscle mass and strength
- Increased body fat, especially visceral
- Loss of body hair, hot flushes (less common)
- Low bone density or osteoporosis on DEXA
Importantly, these symptoms overlap with normal aging, depression, obesity, diabetes, sleep apnea, and thyroid dysfunction—all of which can also lower testosterone. This is why a single testosterone measurement without a thorough clinical evaluation is meaningless.
The Endocrine Society and the European Association of Urology (EAU) recommend diagnosing hypogonadism only when symptoms are present and two separate morning total testosterone measurements (fasting, between 8–10 AM) fall below the lower limit of the normal range for a young healthy male. Free testosterone should be measured if total is borderline or if SHBG is altered (as in obesity, aging, or diabetes).
Country-by-Country: Screening, Diagnosis, and Treatment Cultures
1. United States
Screening culture: The U.S. is unique in the scale of its direct-to-consumer testosterone testing and “anti-aging” clinic industry. Men can order a testosterone panel online, often prompted by aggressive marketing of “Low T” symptoms, and receive results without a physician consultation. This has led to widespread testing and treatment of men with borderline or normal levels.
Guidelines: The Endocrine Society (2018) and the American Urological Association (AUA) provide rigorous diagnostic criteria: consistent symptoms plus two morning total testosterone levels <264 ng/dL (Endocrine Society) or <300 ng/dL (AUA). Free testosterone should be assessed in borderline cases.
Treatment reality: Despite guidelines, real-world practice frequently diverges. Many men with levels between 300–400 ng/dL, or even higher, are prescribed testosterone, often via telemedicine clinics. Testosterone prescribing for men over 40 tripled between 2001 and 2011. The market includes injections, gels, patches, and subcutaneous pellets. A large portion of prescriptions are off-label.
Cardiovascular concern: The FDA requires a label warning about possible increased risk of cardiovascular events, based on conflicting studies. The TRAVERSE trial (2023), a large randomized controlled trial, found no increased major adverse cardiac events (MACE) with transdermal testosterone gel in hypogonadal men with pre-existing cardiovascular disease or risk factors, but some uncertainty persists.
Practical tip: If considering testosterone therapy, seek a board-certified endocrinologist or urologist, not a pop-up clinic. Insist on two fasting morning tests, free testosterone, SHBG, LH, FSH, prolactin, and a baseline hematocrit and PSA before any prescription. Ask about fertility preservation if desired; exogenous testosterone suppresses spermatogenesis.
2. Poland
Screening culture: There is no widespread screening of asymptomatic men. Testosterone testing is initiated primarily by urologists, endocrinologists, or andrologists when a patient presents with suggestive symptoms. Polish men are less exposed to direct-to-consumer hormone marketing, and self-testing is rare.
Guidelines: Polish Society of Endocrinology, Polish Urological Association, and Polish Menopause and Andropause Society follow the EAU and Endocrine Society guidelines. The diagnostic threshold for total testosterone is generally <12 nmol/L (~346 ng/dL) on two morning samples, with free testosterone calculated or measured if borderline. Diagnosis also requires characteristic symptoms.
Treatment approach: Testosterone replacement is accepted for confirmed hypogonadism. Available forms include intramuscular injections (enanthate, sustained-release undecanoate), transdermal gels, and, less commonly, oral preparations. Prescribing is strictly controlled; physicians are cautious about cardiovascular and prostate implications. The cost of some preparations (especially gels) can be high and is not always fully reimbursed, limiting access.
Practical tip: In Poland, a man with fatigue, low libido, and borderline testosterone will often first be advised to improve lifestyle—diet, exercise, sleep, weight loss—for 3–6 months before a prescription is considered. This conservative approach is evidence-based and often effective. If testosterone is eventually prescribed, regular follow-up (every 3–6 months initially) with hematocrit, PSA, and testosterone levels is standard.
3. Germany
Screening culture: Routine screening of asymptomatic men is not recommended, but German urologists and internists frequently check testosterone levels when men present with metabolic syndrome, erectile dysfunction, or osteoporosis. The public is moderately informed; there is less mass-market advertising than in the U.S.
Guidelines: The German Society for Endocrinology and the German Society for Urology endorse the EAU guidelines. The diagnostic cutoff is generally <12.1 nmol/L (350 ng/dL) for total testosterone, with free testosterone considered when total is borderline. The German Medical Association (BÄK) emphasizes that age alone is not an indication for therapy.
Treatment approach: Germany offers a broad range of testosterone preparations, including transdermal gels, short- and long-acting injections, and testosterone undecanoate oral capsules. Bioidentical testosterone is available via compounding pharmacies. Insurance coverage (statutory and private) is generally provided for a confirmed diagnosis. German endocrinologists are meticulous about documenting symptoms and lab values before initiating therapy.
Practical tip: If you’re in your 40s with symptoms suggestive of low testosterone, ask your Hausarzt or urologist: “Könnten wir meinen Testosteronspiegel prüfen, auch mit SHBG?” (Could we check my testosterone level, including SHBG?). They will likely also screen for metabolic syndrome, sleep apnea, and depression, which can mimic hypogonadism. German physicians favor addressing underlying causes before prescribing testosterone.
4. France
Screening culture: France has the most conservative approach of the four countries. Testosterone testing in asymptomatic men is not recommended, and the concept of “andropause” is treated with considerable skepticism by much of the medical community. Screening occurs almost exclusively in the context of clinically evident hypogonadism (e.g., testicular pathology, pituitary disease, severe osteoporosis in a younger man).
Guidelines: The French National Authority for Health (HAS) and the French Endocrinology Society advise diagnosing hypogonadism based on two morning total testosterone values <3 ng/mL (10.4 nmol/L) or calculated free testosterone <70 pg/mL, accompanied by specific symptoms. The threshold is lower than many U.S. labs, reflecting the French emphasis on avoiding overdiagnosis.
Treatment approach: Testosterone therapy is prescribed narrowly, almost exclusively for organic hypogonadism. Aging-related decline alone is not considered a disease warranting treatment. Available forms include injectable enanthate and undecanoate, gel, and transdermal patches. Oral testosterone undecanoate is available but used cautiously. The Agence Nationale de Sécurité du Médicament (ANSM) has issued multiple warnings about the misuse of testosterone, particularly among bodybuilders and athletes.
Practical tip: In France, if you are a man over 40 with fatigue, reduced libido, and mild erectile dysfunction, your médecin traitant will likely explore metabolic, psychological, and vascular causes first—and may not order a testosterone test unless you have hallmark features like loss of body hair, significant muscle wasting, or multiple fragility fractures. If you specifically request a testosterone measurement, it will be done, but a low-normal result will probably not lead to a prescription. French medicine firmly prioritizes lifestyle modification.
Beyond Numbers: The Lifestyle Foundation for Endogenous Testosterone
For the vast majority of 40+ men without organic hypogonadism, lifestyle is the most powerful lever to maintain healthy testosterone levels. Research consistently shows that:
- Weight loss: Obesity, particularly visceral adiposity, suppresses the hypothalamic-pituitary-gonadal axis via aromatization of testosterone to estrogen in fat tissue, elevated leptin, and chronic inflammation. Losing 7–10% of body weight can increase testosterone by 2–3 nmol/L.
- Resistance training: Heavy compound lifting (squats, deadlifts, presses) acutely raises testosterone and, over time, improves body composition and insulin sensitivity, supporting a healthy hormonal environment.
- Sleep optimization: Testosterone is produced during deep sleep. Sleeping less than 5 hours per night reduces testosterone levels by 10–15% within one week. Prioritize 7–8 hours.
- Stress management: Chronic cortisol elevation directly inhibits testosterone synthesis. Mindfulness, yoga, sufficient leisure time, and outdoor physical activity lower cortisol.
- Nutrition: Adequate dietary fat (monounsaturated and omega-3), sufficient zinc (meat, shellfish, legumes, nuts), vitamin D sufficiency, and adequate protein support testosterone production. Avoid severe calorie restriction and excessive alcohol (>2 drinks/day).
These interventions, implemented consistently for 3–6 months, can restore testosterone to normal ranges in many men with lifestyle-induced suppression, and they simultaneously improve cardiovascular and bone health—making them a non-negotiable foundation regardless of whether testosterone therapy is eventually used.
Testosterone Therapy and the Heart-Bone Connection
The decision to start testosterone therapy has implications for the hormone-bone-heart triangle. Testosterone, either directly or after aromatization to estrogen, stimulates bone formation and increases bone mineral density. In hypogonadal men, testosterone therapy consistently improves spine and hip BMD, with effects seen as early as 6 months, and reduces fracture risk in observational studies.
For the heart, the picture is nuanced. Testosterone increases hematocrit, which can elevate blood viscosity and potentially thrombotic risk, and it may worsen sleep apnea. Yet severe hypogonadism is itself associated with increased cardiovascular mortality. The TRAVERSE trial, the largest cardiovascular safety study of testosterone to date, found that transdermal testosterone in hypogonadal men (median age 63) was non-inferior to placebo regarding major adverse cardiovascular events over approximately 3 years, but it was associated with a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism. Thus, the decision requires careful individual cardiovascular risk assessment.
In all four countries, shared decision-making and thorough monitoring are the standard of care. If therapy is initiated, follow-up requires:
- Testosterone levels at 3, 6, and 12 months, then annually.
- Hematocrit and hemoglobin to monitor for polycythemia.
- PSA and digital rectal exam for prostate safety, per national guidelines.
- Bone density monitoring if osteoporosis was a treatment indication.
- Cardiovascular risk factor management (blood pressure, lipids).
The VigorForty Take
Testosterone after 40 is not a “more is better” hormone. It is a tightly regulated system that serves as a barometer of overall metabolic and physical health. At VigorForty, we advocate a country-informed, patient-centered approach:
- In the U.S.: Resist the siren call of direct-to-consumer clinics. If you have symptoms, insist on a comprehensive workup by an endocrinologist or urologist, with two morning tests and full pituitary labs. Prioritize a 6-month lifestyle trial before considering medication.
- In Poland: Work within the system’s cautious, evidence-based approach. See a urologist or endocrinologist, optimize your metabolic health, and view testosterone therapy as a carefully managed second-line tool, not a quick fix.
- In Germany: Use the robust specialist network. Request SHBG and free testosterone if borderline, and expect a holistic evaluation that includes metabolic and sleep screening. German physicians are well-trained to differentiate lifestyle-induced low testosterone from true hypogonadism.
- In France: Accept that the French medical culture will push lifestyle modification aggressively. This is not dismissive—it is protective. Only if symptoms and lab values meet strict clinical criteria will testosterone be prescribed, and then with close surveillance.
For the 40+ man seeking to protect his bones, heart, and hormonal equilibrium, the most effective prescription is often not a testosterone gel but a disciplined commitment to heavy lifting, restorative sleep, body fat reduction, and stress mastery. The numbers on the lab report may follow, but the quality-of-life improvement will precede them.
❓ FAQ Section
1. At what testosterone level should I consider treatment?
Guidelines vary, but generally, two morning total testosterone levels consistently below 300 ng/dL (10.4 nmol/L) accompanied by specific symptoms (low libido, loss of morning erections, etc.) are required for a diagnosis of hypogonadism. Levels between 300–400 ng/dL are a grey zone; free testosterone measurement and clinical context guide the decision. No reputable guideline recommends treatment for levels above 400 ng/dL in the absence of pituitary disease.
2. Will testosterone therapy increase my risk of a heart attack?
The 2023 TRAVERSE trial showed no increase in major adverse cardiac events with transdermal testosterone, but there was a higher rate of atrial fibrillation and other non-fatal events. If you have existing cardiovascular disease, the decision requires a careful risk-benefit discussion with a cardiologist and endocrinologist. Testosterone is not a cardiovascular panacea, and lifestyle should always come first.
3. Can testosterone therapy cause prostate cancer?
Current evidence does not support that testosterone therapy causes prostate cancer. However, it can stimulate growth of an existing prostate cancer. Guidelines require PSA screening before and during therapy. Men with active prostate cancer or high suspicion for it should not receive testosterone.
4. I have low testosterone but want to preserve fertility. Can I take testosterone?
No. Exogenous testosterone suppresses the pituitary hormones LH and FSH, shutting down sperm production. This leads to azoospermia in most men, which is usually reversible upon stopping but can take months to over a year. If you desire future children, discuss alternatives like clomiphene citrate or hCG with a reproductive urologist.
5. Why is the approach to testosterone so different in the U.S. compared to France?
The U.S. has a fee-for-service model that incentivizes testing and prescriptions, direct-to-consumer pharmaceutical advertising (legal since the 1990s), and a cultural emphasis on self-optimization. France has a single-payer system that heavily regulates claims, no direct-to-consumer drug ads, and a deep medical culture that resists medicalizing normal aging. Both systems have strengths and weaknesses; the optimal path lies in rigorous clinical diagnosis wherever you live.
6. How quickly can lifestyle changes raise testosterone?
Weight loss and exercise can raise testosterone within 3–6 months. Studies show that a 10% reduction in body weight through diet and exercise increases testosterone by 2–3 nmol/L. Sleep improvement effects are measurable within a week. These changes may not bring a severely hypogonadal man into the normal range, but for borderline cases, lifestyle alone often resolves both symptoms and lab values.
📚 Research References
- Bhasin S, et al. Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
- Salonia A, et al. EAU Guidelines on Sexual and Reproductive Health. European Association of Urology. 2023.
- Lincoff AM, et al. Cardiovascular safety of testosterone-replacement therapy (TRAVERSE trial). N Engl J Med. 2023;389(2):107–117.
- Corona G, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med. 2014;11(6):1577–1592.
- Grossmann M, et al. Testosterone and body composition in men. Clin Endocrinol (Oxf). 2018;88(2):199–209.
- Traish AM, et al. Adverse health effects of testosterone deficiency in men. Rev Endocr Metab Disord. 2015;16(3):221–238.
- Polskie Towarzystwo Endokrynologiczne. Rekomendacje dotyczące diagnostyki i leczenia hipogonadyzmu u mężczyzn. Endokrynol Pol. 2021.
- Deutsche Gesellschaft für Endokrinologie. S2k-Leitlinie Diagnostik und Therapie des männlichen Hypogonadismus. AWMF-Register Nr. 174/003. 2021.
- Haute Autorité de Santé (HAS). Évaluation des dispositifs de dosage de la testostérone. 2020.
- Snyder PJ, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611–624. (Testosterone Trials)
